Isogambogenic acidCAS# 887923-47-9 |
- Gambogenic acid
Catalog No.:BCN3077
CAS No.:173932-75-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 887923-47-9 | SDF | Download SDF |
| PubChem ID | 70639870 | Appearance | Powder |
| Formula | C38H46O8 | M.Wt | 630.8 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC(=CCCC(=CCC1=C(C2=C(C(=C1O)CC=C(C)C)OC34C5CC(C=C3C2=O)C(=O)C4(OC5(C)C)CC=C(C)C(=O)O)O)C)C | ||
| Standard InChIKey | RCWNBHCZYXWDOV-ZTZLKAGZSA-N | ||
| Standard InChI | InChI=1S/C38H46O8/c1-20(2)10-9-11-22(5)13-15-25-30(39)26(14-12-21(3)4)33-29(31(25)40)32(41)27-18-24-19-28-36(7,8)46-37(34(24)42,38(27,28)45-33)17-16-23(6)35(43)44/h10,12-13,16,18,24,28,39-40H,9,11,14-15,17,19H2,1-8H3,(H,43,44)/b22-13+,23-16+/t24-,28?,37?,38-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Isogambogenic acid inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis therapy. 2. Isogambogenic acid exhibits an anticancer effect by inducing autophagy-dependent cell death in NSCLC cells, which may be an effective chemotherapeutic agent that can be used against NSCLC in a clinical setting. |
| Targets | Bcl-2/Bax | Caspase | mTOR | VEGFR | Akt | MAPK |
Isogambogenic acid Dilution Calculator
Isogambogenic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5853 mL | 7.9264 mL | 15.8529 mL | 31.7058 mL | 39.6322 mL |
| 5 mM | 0.3171 mL | 1.5853 mL | 3.1706 mL | 6.3412 mL | 7.9264 mL |
| 10 mM | 0.1585 mL | 0.7926 mL | 1.5853 mL | 3.1706 mL | 3.9632 mL |
| 50 mM | 0.0317 mL | 0.1585 mL | 0.3171 mL | 0.6341 mL | 0.7926 mL |
| 100 mM | 0.0159 mL | 0.0793 mL | 0.1585 mL | 0.3171 mL | 0.3963 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Gaudichaudic acid
Catalog No.:BCN3071
CAS No.:887923-46-8
- Bafetinib (INNO-406)
Catalog No.:BCC4036
CAS No.:887650-05-7
- (-)-Holostyligone
Catalog No.:BCN2863
CAS No.:887501-28-2
- Fmoc-Arg(Mts)-OH
Catalog No.:BCC3075
CAS No.:88743-97-9
- INCB 3284 dimesylate
Catalog No.:BCC1646
CAS No.:887401-93-6
- 3,9-Dihydroeucomin
Catalog No.:BCN6832
CAS No.:887375-68-0
- K-115
Catalog No.:BCC5500
CAS No.:887375-67-9
- Hebeirubescensin H
Catalog No.:BCN7155
CAS No.:887333-30-4
- Epiglobulol
Catalog No.:BCN7121
CAS No.:88728-58-9
- Adynerigenin beta-neritrioside
Catalog No.:BCN4556
CAS No.:88721-09-9
- 1alpha-Hydroxytorilin
Catalog No.:BCN6648
CAS No.:887147-75-3
- Borneol 7-O-[beta-D-apiofuranosyl-(1->6)]-beta-D-glucopyranoside
Catalog No.:BCN7814
CAS No.:88700-35-0
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Sprengerinin C
Catalog No.:BCN6657
CAS No.:88861-91-0
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.[Pubmed:24070138]
J Chemother. 2013 Oct;25(5):298-308.
Isogambogenic acid (iso-GNA) is a well-known herbal medicine extracted from Garcinia hanburyi. Although it is thought to have anti-tumour effects, its function is still unknown. This study carried out in vitro and in vivo evaluations of the anti-tumour and anti-angiogenic activity of iso-GNA and underlying mechanisms. A standard methyl thiazolyl tetrazolium assay showed that iso-GNA was more effective in inhibiting the proliferation of human umbilical vascular endothelial cells than A549 cancer cells. Iso-GNA demonstrated potent anti-angiogenic activity and low toxicity at appropriate concentrations in zebrafish embryos. In a xenograft nude mouse model of lung tumour, iso-GNA effectively inhibited tumour growth and tumour angiogenesis. Iso-GNA suppressed neovascularization of implanted matrigel plugs in vivo and inhibited vascular endothelial growth factor (VEGF)-induced microvessel sprouting from mouse aortic rings ex vivo. Iso-GNA inhibited VEGF-induced migration, invasion, and tube formation in vitro and affected cytoskeletal rearrangement in human umbilical vascular endothelial cells. The results show that iso-GNA suppressed angiogenesis-mediated tumour growth by targeting VEGFR2, Akt, mitogen-activated protein kinase, Rho GTPase, vascular endothelium-cadherin, and focal adhesion kinase signalling pathways. Together, these data suggest that iso-GNA inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies.
Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells.[Pubmed:25571970]
Sci Rep. 2015 Jan 9;5:7697.
To overcome drug resistance caused by apoptosis deficiency in patients with non-small cell lung carcinoma (NSCLC), there is a need to identify other means of triggering apoptosis-independent cancer cell death. We are the first to report that Isogambogenic acid (iso-GNA) can induce apoptosis-independent autophagic cell death in human NSCLC cells. Several features of the iso-GNA-treated NSCLC cells indicated that iso-GNA induced autophagic cell death. First, there was no evidence of apoptosis or cleaved caspase 3 accumulation and activation. Second, iso-GNA treatment induced the formation of autophagic vacuoles, increased LC3 conversion, caused the appearance of autophagosomes and increased the expression of autophagy-related proteins. These findings provide evidence that iso-GNA induces autophagy in NSCLC cells. Third, iso-GNA-induced cell death was inhibited by autophagic inhibitors or by selective ablation of Atg7 and Beclin 1 genes. Furthermore, the mTOR inhibitor rapamycin increased iso-GNA-induced cell death by enhancing autophagy. Finally, a xenograft model provided additional evidence that iso-GNA exhibited anticancer effect through inducing autophagy-dependent cell death in NSCLC cells. Taken together, our results demonstrated that iso-GNA exhibited an anticancer effect by inducing autophagy-dependent cell death in NSCLC cells, which may be an effective chemotherapeutic agent that can be used against NSCLC in a clinical setting.
